InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,522.30
(
1.58%
)
US TECH 100
19,012.00
(
3.88%
)
Dow Jones
40,842.79
(
0.24%
)
Brent Oil
81.49
(
-0.03%
)
Bitcoin
63,817.83
(
-1.21%
)
Post# of 29488
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120173
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 2501

Thursday, 07/21/2011 1:32:04 AM

Thursday, July 21, 2011 1:32:04 AM

Post# of 29488
Re: Branded generics in emerging markets

ABT’s 2Q11 sales of branded generics in emerging markets grew 25% YoY to an annualized rate of $3.1B. ABT’s 2Q11 overall sales of drugs and devices in emerging markets grew 26% YoY to an annualized rate of $10.4B.

NVS’ 2Q11 sales (branded + generic) grew 36% and 20% YoY, respectively, in China and India. (NVS does not disclose sales numbers or growth rates for emerging markets in the aggregate.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up